Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOPE HIM: Eptacog Beta for Prevention of Bleeding in Hemophilia Patients Undergoing Surgery
NCT05695391Phase 3Terminated
- Sponsor
- LFB Group
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of coagulation factor VIIa in hemophilia A and hemophilia B (HB), sponsored by LFB Group. Primary endpoint: Eptacog Beta (Activated) (EB) Effectiveness Based on Protocol's Aggregate Score at 120 hours. Started Jun 2024; status: terminated.
02
Drugs
coagulation factor VIIa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT05695391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695391.